Parse Biosciences, a leader in affordable and scalable single-cell sequencing solutions, has launched Parse GigaLab™, designed to enable single-cell sequencing for billions of cells annually. GigaLab utilizes Parse’s Evercode™ technology, enhanced by an expanded workflow and increased automation, facilitating groundbreaking discoveries that traditional single-cell methods couldn’t achieve.
GigaLab is designed for researchers aiming to scale their projects to 10 million cells or more, with a current capacity for profiling 2.5 billion cells annually. Several initial projects in GigaLab are set to surpass the total number of cells available in all public single-cell datasets combined. These advancements will be particularly valuable for large-scale drug and perturbation analyses, generative AI datasets, and population studies.
In partnership with Ultima Genomics, Parse successfully conducted the first experiment involving 10 million cells from 1,092 samples in a single run, completing barcoding and library preparation in just three days. This pioneering study assessed 90 cytokine perturbations across 18 immune cell types from 12 PBMC donors, yielding over 19,000 observed perturbations. Collaborating with Professor Fabian Theis from Helmholtz Munich, whose lab developed the computational tool Scanpy, they are analyzing this dataset to refine new AI models.
“Large-scale single-cell perturbation datasets are essential for building predictive models in health and disease,” stated Dr. Theis. He praised Parse’s ability to rapidly deliver these datasets, saying it will significantly accelerate discoveries.
Charlie Roco, PhD, Chief Technology Officer and Co-Founder of Parse, noted, “Researchers are now routinely profiling 1 million cells or nuclei per experiment with our existing kits. With GigaLab, we are redefining what’s possible in single-cell analysis to enhance biological discovery and human health.”
Parse will showcase GigaLab’s capabilities at the upcoming American Society of Human Genetics (ASHG) conference, presenting on November 6 at 2:30 p.m. and exhibiting at booth #703.
About Parse Biosciences
Parse Biosciences is a global life sciences company dedicated to advancing human health and scientific research. Its innovative approach allows researchers to sequence single cells at unprecedented scale, leading to breakthroughs in areas like cancer treatment, tissue repair, and immune system research.
Founded by Alex Rosenberg and Charles Roco, Parse has raised over $100 million and serves over 2,000 customers worldwide. Its product portfolio includes Evercode™ Whole Transcriptome, Evercode™ TCR, Evercode™ BCR, Gene Select, and the data analytics solution Trailmaker™. Headquartered in Seattle’s South Lake Union district, Parse has recently expanded into a new state-of-the-art facility.
